SCMP Group Ltd. ADS (SCPXY) Financials Nov 6, 2014, 8:10

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
SCMP Group Ltd. ADS (SCPXY) Financials Nov 6, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for SCMP Group Ltd. ADS


Fiscal year is January-December. All values HKD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 740.67M 881.08M 946.08M 1.02B 1.15B
Cost of Goods Sold (COGS) incl. D&A 506.99M 544.73M 600.59M 685.3M 822.47M
COGS excluding D&A 450.23M 488.39M 548M 630.27M 761.68M
Depreciation & Amortization Expense 56.76M 56.34M 52.59M 55.03M 60.79M
Depreciation 48.63M 48.48M 47.01M 48.33M 49.09M
Amortization of Intangibles 8.14M 7.87M 5.57M 6.7M 11.7M
Gross Income 233.68M 336.35M 345.49M 334.31M 324.15M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 184.47M 178.5M 147.93M 157.73M 159.84M
Research & Development 0 0 0 0 0
Other SG&A 184.47M 178.5M 147.93M 157.73M 159.84M
Other Operating Expense 0 0 0 0 0
Unusual Expense (134.65M) (198.8M) (237.65M) (170.65M) (85.75M)
EBIT after Unusual Expense 134.65M 198.8M 237.65M 170.65M 85.75M
Non Operating Income/Expense 1.36M 8.43M 11.83M 8.33M 9.69M
Non-Operating Interest Income 1.11M 2.46M 4.47M 4.82M 4.3M
Equity in Affiliates (Pretax) 0 0 1.49M 6.77M 7.52M
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income 186.32M 367.54M 453.01M 367.14M 271.56M
Income Tax 34.81M 67.31M 30.15M 33.99M 27.49M
Income Tax - Current Domestic 15.32M 38.53M 31.21M 33.55M 31.18M
Income Tax - Current Foreign 48,000 136,000 245,000 424,000 531,000
Income Tax - Deferred Domestic 19.45M 28.65M (1.3M) 16,000 (4.23M)
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates (3.43M) 5.76M 0 - -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 148.07M 305.99M 422.85M 333.15M 244.07M
Minority Interest Expense 9.92M 11.62M 12.93M 16.87M 20.34M
Net Income 138.15M 294.38M 409.92M 316.28M 223.73M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 138.15M 294.38M 409.92M 316.28M 223.73M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 138.15M 294.38M 409.92M 316.28M 223.73M
EPS (Basic) 0.09 0.19 0.26 0.20 0.14
Basic Shares Outstanding 1.56B 1.56B 1.56B 1.56B 1.56B
EPS (Diluted) 0.09 0.19 0.26 0.20 0.14
Diluted Shares Outstanding 1.56B 1.56B 1.56B 1.56B 1.56B
EBITDA 105.96M 214.19M 250.15M 231.6M 225.11M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 61

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 69

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 181

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 28

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 80

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 331

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Warner Bros. Discovery's Remarkable Stock Surge Explained

Updated Category News Views 309

Warner Bros. Discovery Experiences Impressive Stock Surge Warner Bros. Discovery Inc. (NASDAQ: WBD) has been making headlines recently, with its stock surging dramatically. Investors and market enthusiasts are keenly observing this upward trend, particularly following a substantial rally. Record-Breaking Rally The company achieved an incredible milestone with its largest...

Continue Reading
Stellantis Reports 20% Q3 Shipment Drop, Market Reactions

Updated Category News Views 98

Stellantis Faces Significant Q3 Shipment Decline Stellantis (EPA: STLAM) (NYSE: STLA) recently reported a 20% drop in global shipments for the third quarter, prompting a notable reaction in the markets. The decline has been attributed to several factors including strategic inventory reduction measures and delays in the release of new models. During this challenging...

Continue Reading
Stifel Affirms Buy Rating on Elanco Amid New Drug Approval

Updated Category News Views 70

Stifel Stands Firm on Elanco Animal Health Stifel, a prominent financial services firm, has recently reaffirmed its Buy rating for Elanco Animal Health (NYSE: ELAN) and has kept its price target at $20.00 per share. This decision comes on the heels of the U.S. Food and Drug Administration's (FDA) approval of Elanco's new drug, Zenrelia, which serves as a significant boost...

Continue Reading
ChargePoint and Siemens Drive EV Infrastructure Innovation

Updated Category News Views 94

ChargePoint and Siemens Lead the Charge in Clean Tech The clean tech revolution is moving at an impressive pace, particularly with the growth of electric vertical takeoff and landing (eVTOL) aircraft and electric vehicle (EV) infrastructure. Companies like ChargePoint Holdings Inc (NYSE: CHPT) and Siemens AG (OTCPK: SIEGY) are crucial in shaping a sustainable future for...

Continue Reading
Elevance Health Faces Class Action: Investors Seek Remedies

Updated Category News Views 259

Opportunities for Investors in Elevance Health Class Action The recent developments surrounding Elevance Health, Inc. have prompted considerable attention, particularly among investors who have experienced substantial financial losses. The law firm Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit targeting Elevance Health, which operates in the health...

Continue Reading